WuXi Biologics Announces Positive Profit Alert
SHANGHAI, March 5, 2018 /PRNewswire/ -- WuXi Biologics (Stock Code: 2269.HK), a leading global open-access biologics technology platform company that offers end-to-end solutions for biologics discovery, development and manufacturing, announced that based on the preliminary assessment of the unaud...
WuXi Biologics Congratulates MabSpace on FDA Clearance of IND for MSB2311
SHANGHAI, Feb. 26, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, congratulates its partner MabSpace Biosciences for FDA Investigational New ...
WuXi Biologics Congratulates Tychan for Dosing First Patient of a Zika Antibody after Record 9 Months of Development
SHANGHAI, Feb. 8, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today congratulated its partner Tychan for dosing the first patient with a fir...
WuXi Biologics Congratulates BioAtla on FDA Clearance of IND Application for CAB-AXL-ADC
SHANGHAI, Jan. 30, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, congratulates its partner BioAtla® LLC for U.S. Investigational New Drug appli...
WuXi Biologics and Aravive Biologics to Form Strategic Manufacturing Collaboration Following Successful IND Filing for AVB-S6-500
WUXI, China and HOUSTON, Jan. 29, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Aravive Biologics, Inc., today announced plans to expand...
WuXi Biologics Announces Formation of Scientific Advisory Board
SHANGHAI, Jan. 24, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced the appointment of five internationally recognized scientis...
WuXi Biologics Appoints Dr. Chiang Syin, a Former FDA Officer as Chief Quality Officer
WUXI, China, Jan. 14, 2018 /PRNewswire/ -- WuXi Biologics (WuXi Bio, 02269.HK), a leading global open-access biologics technology platform company, offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce that Dr. Chiang Syin has joined WuXi ...
WuXi Biologics and Phanes Sign MOU and Announce Strategic Development and Manufacturing Partnership
SHANGHAI and SAN DIEGO, Dec. 14, 2017 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Phanes Therapeutics, Inc. (Phanes), an innovative drug di...
WuXi Biologics Initiated cGMP Manufacturing in the World's Largest Biologics Manufacturing Facility Using Only Single-Use Bioreactors
WUXI, China, Dec. 6, 2017 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company, offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that its cGMP biologics manufacturing facility in Wuxi c...
WuXi Biologics and Pall Corporation Establish Joint Continuous Bioprocess Laboratory
SHANGHAI, Nov. 2, 2017 /PRNewswire/ -- WuXi Biologics (2269.HK), a global leading open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and its partner Pall Corporation, the global leader of advanced filtration, ...
WuXi Biologics Announces 2017 Interim Results
HONG KONG, Aug. 22, 2017 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announces...
WuXi Biologics and Gloria Pharmaceuticals Announce the Licensure of the Fully Human PD-1 Antibody, GLS-010, to Arcus Biosciences
SHANGHAI and BEIJING, Aug. 17, 2017 /PRNewswire/ -- WuXi Biologics (2269.HK), a global leading open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and its Chinese partner Harbin Gloria Pharmaceuticals Co Ltd (0...
WuXi Biologics is Officially Listed on the Hong Kong Stock Exchange
HONG KONG, June 13, 2017 /PRNewswire/ -- On June 13, 2017, WuXi Biologics (Cayman) Inc. ("the Company"; stock code: 2269.HK) was officially listed during a grand listing ceremony at the Main Board of The Stock Exchange ofHong Kong. Dr.Ge Li, Group Chairman and CEO of WuXi AppTec and Chairman o...
